Availability and Approval

Retatrutide is not currently available for prescription or purchase. It is in Phase 3 clinical development. Eli Lilly indicated during its Q4 2025 earnings call (February 4, 2026) that NDA filing is expected in late 2026. Based on this guidance, FDA approval could come as early as mid-2027 (if Priority Review is granted) or late 2027 to early 2028 under standard review. These are estimates and are subject to change based on trial outcomes and regulatory processes.

The only legitimate way to receive retatrutide currently is through participation in an authorized clinical trial. The drug is not approved for prescription, and purchasing it outside of a clinical trial setting is not sanctioned by regulatory authorities. We strongly advise against obtaining any investigational compound through unregulated channels.

In all clinical trials to date, retatrutide has been administered as a once-weekly subcutaneous injection. If approved, it is expected to be available initially as an injectable formulation. Whether an oral formulation might be developed in the future is unknown and would require separate clinical development.

Pricing has not been determined, as retatrutide has not been approved for marketing. For context, other incretin-based obesity medications (semaglutide, tirzepatide) carry list prices in the range of approximately $1,000-$1,300 per month in the United States, though net prices after insurance and rebates vary widely. Retatrutide pricing will depend on its approved indications, competitive positioning, insurance coverage decisions, and Eli Lilly's pricing strategy.

Insurance coverage decisions cannot be predicted at this time. Coverage for obesity medications has historically been limited, though it has been expanding in recent years as the medical community increasingly recognizes obesity as a chronic disease requiring pharmacological treatment. Coverage will depend on the approved indications, individual insurance plans, and payer policies at the time of potential approval.

If retatrutide receives FDA approval, Eli Lilly would be expected to pursue regulatory submissions in other major markets, including the European Union (through the EMA), Japan, Canada, Australia, and other countries. International approval timelines typically lag behind U.S. approval by 6-18 months, depending on the regulatory agency and submission timing.